PDF(1142 KB)
PDF(1142 KB)
PDF(1142 KB)
青少年炎症性肠病伴生长激素缺乏4例并文献复习
Inflammatory bowel disease with growth hormone deficiency in adolescents: an analysis of 4 cases and literature review
炎症性肠病（IBD）为慢性复发性非特异性肠道炎症性病变，10%~56%的克罗恩病患儿和10%左右的溃疡性结肠炎患儿存在生长迟缓。该研究报道4例伴生长激素缺乏的青少年IBD（均为克罗恩病），其中男3例、女1例，确诊年龄11.0~13.9岁，确诊时病程11~85个月。4例患儿的病灶分别为：单纯小肠、单纯结肠、小肠及上消化道、小肠及结肠均累及，克罗恩病活动指数27.5~45分。4例患儿的年龄别身高Z评分（HAZ）均 < -2，生长激素刺激试验均提示生长激素缺乏症。2例患儿接受了重组人生长激素联合英夫利西单抗治疗，1例仅接受英夫利西单抗治疗，另1例接受重组人生长激素联合巯嘌呤的治疗。所有患儿经治疗后HAZ评分均有改善。
Inflammatory bowel disease (IBD) is a chronic recurrent non-specific inflammatory disease in the intestinal tract. About 10%-56% of children with Crohn's disease and about 10% of children with ulcerative colitis have growth retardation. This study reports four adolescents with IBD and growth hormone deficiency who were diagnosed with Crohn's disease. There were three boys and one girl, with an age of 11.0-13.9 years and a disease duration of 11-85 months at diagnosis. The four patients had the involvement of the small intestine only, the colon only, both the small intestine and the upper gastrointestinal tract, and both the small intestine and the colon respectively. The pediatric Crohn's disease activity index ranged from 27.5 to 45 points. All four patients had a height-for-age Z-score (HAZ) of < -2, and the growth hormone provocative test suggested growth hormone deficiency. Of all four patients, two received recombinant human growth hormone combined with infliximab, one received infliximab only, and one received recombinant human growth hormone combined with mercaptopurine. All four patients had an improvement in HAZ after treatment.
Inflammatory bowel disease / Crohn's disease / Growth hormone deficiency / Adolescent
[1] Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease:incidence, prevalence, and environmental influences[J]. Gastroenterology, 2004, 126(6):1504-1517.
[2] Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset inflammatory bowel disease:a systematic review[J]. J Clin Gastroenterol, 2012, 46(7):581-589.
[3] Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease[J]. J Crohns Colitis, 2014, 8(10):1179-1207.
[4] Levine A, Koletzko S, Turner D, et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents[J]. J Pediatr Gastroenterol Nutr, 2014, 58(6):795-806.
[5] 中华医学会儿科学分会内分泌遗传代谢学组. 矮身材儿童诊治指南[J]. 中华儿科杂志, 2008, 46(6):428-430.
[6] El Mouzan MI, Al Mofarreh MA, Saadah OI, et al. Impact of pediatric inflammatory bowel disease on linear growth:Data from a national cohort study in Saudi Arabia[J]. Saudi J Gastroenterol, 2016, 22(2):106-108.
[7] Malik S, Mason A, Bakhshi A, et al. Growth in children receiving contemporary disease specific therapy for Crohn's disease[J]. Arch Dis Child, 2012, 97(8):698-703.
[8] Gasparetto M, Guariso G. Crohn's disease and growth deficiency in children and adolescents[J]. World J Gastroenterol, 2014, 20(37):13219-13233.
[9] Ezri J, Marques-Vidal P, Nydegger A. Impact of disease and treatment on growth and puberty of pediatric patients with inflammatory bowel disease[J]. Digestion, 2012, 85(4):308-319.
[10] Song SM, Kim Y, Oh SH, et al. Nutritional status and growth in Korean children with Crohn's disease:a single-center study[J]. Gut Liver, 8(5):500-507.
[11] Witkowska-S?dek E, Labochka D, Majcher A, et al. The pretreatment characteristics and evaluation of the effects of recombinant human growth hormone therapy in children with growth hormone deficiency and celiac disease or inflammatory bowel disease[J]. Cent Eur J Immunol, 2018, 43(1):69-75.
[12] Soendergaard C, Young JA, Kopchick JJ. Growth hormone resistance-special focus on inflammatory bowel disease[J]. Int J Mol Sci, 2017, 18(5):E1019.
[13] Gupta N, Lustig RH, Kohn MA, et al. Sex differences in statural gowth impairment in Crohn's disease:Role of IGF-1[J]. Inflamm Bowel Dis, 2011, 17(11):2318-2325.
[14] Thayu M, Denson LA, Shults J, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease[J]. Gastroenterol, 2010, 139(2):430-438.
[15] Shamir R. Nutrition and growth in inflammatory bowel disease[J].World Rev Nutr Diet, 2013, 106:156-161.
[16] Herzog D, Fournier N, Buehr P, et al. Early-onset Crohn's disease is a risk factor for smaller final height[J]. Eur J Gastroenterol Hepatol, 2014, 26(11):1234-1239.
[17] Pfefferkorn M, Burke G, Griffiths A, et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms[J]. J Pediatr Gastroenterol Nutr, 2009, 48(2):168-174.
[18] Pichler J, Hanslik A, Huber WD, et al. Paediatric patients with inflammatory bowel disease who received infliximab experienced improved growth and bone health[J]. Acta Paediatr, 2014, 103(2):e69-75.
[19] Walters TD, Faudion WA, Griffiths AM, et al. Growth improvement with adalimumab treatment in children with moderately to severely active Crohn's disease[J]. Inflamm Bowel Dis, 2017, 23(6):967-975.
[20] Hansen T, Duerksen DR. Enteral Nutrition in the management of pediatric and adult Crohn's disease[J]. Nutrients, 2018, 10(5). pii:E537.
[21] Cameron FL, Gerasimidis K, Papangelou A, et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease[J]. Aliment Pharmacol Ther, 2013, 37(6):622-629.
[22] Phung OJ, Coleman CI, Baker EL, et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis[J]. Pediatrics, 2010, 126(5):E1211-E1226.
[23] Bechtold S, Dalla Pozza R, Schwarz HP, et al. Effects of growth hormone treatment on growth in children with juvenile idiopathic arthritis[J]. Horm Res, 2009, 72(Suppl 1):55-59.
[24] Wong SC, Kumar P, Galloway PJ, et al. A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn's disease[J]. Clin Endocrinol(Oxf), 2011, 74(5):599-607.
